Cerêve was a medical device company focused on developing novel therapies for central nervous system disorders, with a particular emphasis on sleep-based interventions for neurodegenerative diseases and insomnia["@cerve"].
...
Company: Cerêve, Inc.
Headquarters: Madison, Wisconsin, USA
Founded: 2014
Acquired: 2021 (by Zogenix), 2022 (by UCB)
Status: Commercial stage (sleep system), Research discontinued (AD program)
Overview
Mermaid diagram (expand to render)
Cerêve was a medical device company focused on developing novel therapies for central nervous system disorders, with a particular emphasis on sleep-based interventions for neurodegenerative diseases and insomnia["@cerve"].
The company pioneered a unique approach to neurological treatment by targeting the glymphatic system—a brain waste clearance mechanism that is most active during sleep. Their technology was based on groundbreaking research from the University of Wisconsin-Madison demonstrating that targeted cooling of the forehead could enhance the brain's natural clearance of toxic proteins associated with [Alzheimer's disease](/diseases/alzheimers-disease).
Funding
Acquired: 2017 by Merck ($1B)
Corporate Profile
| Attribute | Details | |-----------|---------| | Headquarters | Madison, Wisconsin, USA | | Founded | 2014 | | Acquired | 2021 by Zogenix ($100M); 2022 by UCB | | Focus | Sleep-based drug delivery, neurological devices | | Status | Commercial (sleep system), Discontinued (AD program) |
Pipeline
Technology Platform
Sleep-Delivery System
Cerêve developed an innovative approach to delivering therapeutics through targeted sleep modulation. The Cerêve Sleep System was a medical device designed to cool the forehead during sleep[@fda]:
Device Components
Cooled Delivered System: A wearable device that circulates cooled fluid through a pad worn on the forehead
Temperature control: Precise cooling to a target temperature (typically 68-72°F / 20-22°C)
Insomnia disorder: Improve sleep onset and maintenance
Alzheimer's disease: Enhance clearance of [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) proteins during sleep
Key Programs
| Program | Indication | Stage | Status | |---------|------------|-------|--------| | Cerêve Sleep System | Insomnia disorder | FDA Cleared | Commercial | | Controlled Cortical Impact | Traumatic brain injury | Preclinical | Research | | Sleep-Based Drug Delivery | Alzheimer's disease | Research | Discontinued |
Cerêve Sleep System (Commercial)
The Cerêve Sleep System received FDA 510(k) clearance for the treatment of insomnia disorder:
Mechanism: Forehead cooling reduces core body temperature, facilitating sleep onset
Clinical data: Demonstrated improvement in sleep onset latency in pivotal trials
Target population: Patients with difficulty falling asleep
Sleep-Based Drug Delivery (Discontinued)
The Alzheimer's disease program was based on enhanced glymphatic clearance:
Rationale: Cooling the forehead would increase temperature gradient in the brain, enhancing CSF flow
Stage: Research/discontinued prior to clinical development
Status: Program not continued after Zogenix acquisition
Scientific Rationale
The Glymphatic System
The [glymphatic system](/entities/glymphatic-system) is a brain-wide waste clearance mechanism discovered by Dr. Maiken Nedergaard and colleagues at the University of Rochester[@iliff2013]:
Cerebrospinal fluid (CSF) flows through the brain's perivascular spaces
Astrocyte water channels (AQP4) facilitate fluid movement into brain tissue
Waste products (including amyloid-beta and tau) are cleared into the lymphatic vessels
Activity: Most active during slow-wave sleep
Sleep and Neurodegeneration
Research has established connections between sleep disturbance and neurodegenerative disease:
Amyloid-beta: Levels in CSF increase during wakefulness, decrease during sleep
Tau: Sleep deprivation accelerates tau pathology in animal models
Clinical observations: Sleep disorders are a risk factor for AD/PD